Navigation Links
Chinese Biopharmaceutical Association Holds 15th Annual Conference in Rockville, MD, June 12 - 13
Date:5/23/2010

The Chinese Biopharmaceutical Association-USA (CBA) announced today that it is holding its 15th Annual Conference June 12 -13 in Maryland, US. The event will highlight current breakthroughs, new opportunities and future challenges in biopharmaceutical development. It will also develop a platform for communication and collaboration among biopharmaceutical companies, CROs, research institutions and government agencies, as well as individual research scientists, biopharmaceutical executives, entrepreneurs and venture capitalists.

Potomac, MD (PRWEB) May 21, 2010 -- The Chinese Biopharmaceutical Association-USA (CBA) announced today that it is holding its 15th Annual Conference June 12 -13 in Maryland, US.

The event will highlight current breakthroughs, new opportunities and future challenges in biopharmaceutical development. It will also develop a platform for communication and collaboration among biopharmaceutical companies, CROs, research institutions and government agencies, as well as individual research scientists, biopharmaceutical executives, entrepreneurs and venture capitalists.
With an anticipated attendance of more than 500, the conference offers a unique opportunity for those interested in fostering collaborations.

“The goal of our annual conference is to provide a place for bio-life scientists and executives interested in developing and establishing global networks and partnerships to meet, share needs and opportunities and develop relationships that can grow into powerful collaborations across the border,” said Sujuan Ba, Ph.D., chairperson of the conference and President-elect of the Chinese Biopharmaceutical Association – USA. “Many partnerships have been built on the base of the relationships made from the networking and discussions during our past conferences.”

More than 30 distinguished speakers will be present, including keynote speakers Dr. Eric Green, Director, National Human Genome Research Institute, National Institutes of Health; Mr. Gabriel Leung, President, Pharmaceuticals Business, OSI Pharmaceuticals; Dr. Lynda Chin, Dana-Farber Cancer Institute, Harvard Medical School; Dr. Jonathan Yingling, Vice President of Cancer Research, Eli Lilly; and Dr. Herren Wu, Vice President, Global Head of Technology and Lead Generation of MedImmune.

During the conference, CBA will announce and present its annual CBA Brilliant Achievement Award, established in 1994 to honor outstanding individuals who have made seminal contributions to science, technology or business development in the biopharmaceutical fields. The recipient must also have moved medicine in new directions and have been actively involved in building collaborative efforts internationally to advance medical fields.

The award aims to promote public awareness of the importance of collaborations between basic and applied researchers, between academia and industry, and between researchers and entrepreneurs.

The theme of this year’s conference is Biopharmaceutical Medicines: Development and Commercialization without Borders. The conference program includes:

 
  • An insider’s view of the current state of biopharmaceutical development and commercialization
  • An emerging center for biopharmaceutical R&D – showcasing China’s biotech parks and partnering opportunities
  • Novel therapeutics and companion diagnostics
  • Regulatory landscape for biosimilars
  • Stem cells: from metabolic syndrome to cancer
  • Pathways to success in China – a bird’s-eye view through case studies

For more information or to register for the conference, please visit www.cba-usa.org or e-mail event(at)cba-usa(dot)org. Attendance is limited and media is highly encouraged to attend.

About the Chinese Biopharmaceutical Association - USA

The Chinese Biopharmaceutical Association – USA (CBA) is one of the largest Chinese American professional associations in the United States. Founded in 1995, CBA is an independent, non-political, not for-profit professional organization dedicated to promoting science, technology, and business development in the biopharmaceutical fields by fostering research and business collaborations around the world. The Association is led by its elected board of directors and executive committee. For more information about the CBA and its programs, visit www.cba-usa.org.

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb4034904.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
2. ARIUS to present at Chinese Global Financial Forum
3. AMDLs Chinese Subsidiary Wins Key Brand Excellence Award for Anti-Aging Treatment
4. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
5. Aida Receives Chinese Government Innovation Award
6. China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
7. AMDL Wins Chinese Military Supply Agreement for Its Domperidone Product for up to $6.6 Million
8. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
9. Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation
10. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
11. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017  MIODx ... license for two key immunotherapy technologies from the ... technology provides a method to monitor a patient ... as PD-L1 and CTLA-4.  The second license extends ... a patient is likely to have an immune-related ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
(Date:2/23/2017)... Feb. 23, 2017 Aviva Systems Biology ... the acquisition of GenWay Biotech Incorporated, a protein ... and product offering for both the research and ... growth and enhance capabilities for both entities. GenWay,s 18 ... assays will nicely complement ASB,s objective to become ...
Breaking Biology Technology:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
Breaking Biology News(10 mins):